UNSPSC 51162012: Budesonide/formoterol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162012 Budesonide/formoterol, a Commodity code, does not align with recent state and local procurement activity. The code nominally covers a specific combination inhaled corticosteroid and long-acting beta-agonist pharmaceutical, but the four most recent opportunities tagged to this code in state and local markets are instead soliciting naloxone and drug deactivation systems, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products. These solicitations span distinctly different therapeutic categories, procurement models, and operational scopes from the code's defined product, indicating a classification mismatch rather than an active market for budesonide/formoterol specifically under this taxonomy entry.

The absence of budesonide/formoterol-specific solicitations suggests minimal recent demand under this Commodity code in state and local procurement. Practitioners pursuing pharmaceutical contracts through state and local channels should verify the correct UNSPSC classification for respiratory combination therapies or monitor broader pharmaceutical family codes that encompass inhaled products, rather than rely on this specific code to surface relevant opportunities.